Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Molatore, Sara ^a   Kiermaier, Eva ^a,b   Jung, Christian B ^a,c   Lee, Misu ^a   Pulz, Elke ^a   Höfler, Heinz ^a,d   Atkinson, Michael J ^a   Pellegata, Natalia S ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLIN DEPENDENT KINASE; CYCLINE; MICRORNA; MICRORNA 221; MICRORNA 222; MUTANT PROTEIN; PROTEASOME; PROTEIN P27; PROTEIN P27FS177; S PHASE KINASE ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1B;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL NUCLEUS; CONTROLLED STUDY; EMBRYO; FIBROBLAST; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TRANSPORT; RAT; REGULATORY MECHANISM; WILD TYPE; ANIMAL; CELL CULTURE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; MOUSE; MUTATION; WESTERN BLOTTING;

ANIMALIA; MUS; RATTUS;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOPRECIPITATION; MICE; MULTIPLE ENDOCRINE NEOPLASIA; MUTATION; RATS; TRANSFECTION;

EID: 77952463207     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-116     Document Type: Article

References (33)

1. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1502. 10.1101/gad.13.12.1501, 10385618.
2. Philipp-Staheli J, Payne SR, Kemp CJ. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001, 264:148-168. 10.1006/excr.2000.5143, 11237531.
3. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997, 11:1464-1478. 10.1101/gad.11.11.1464, 9192873.
4. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 1997, 16:5334-5344. 10.1093/emboj/16.17.5334, 1170165, 9311993.
5. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999, 1:193-199. 10.1038/12013, 10559916.
6. Besson A, Hwang HC, Cicero S, Donovan SL, Gurian-West M, Johnson D, Clurman BE, Dyer MA, Roberts JM. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007, 21:1731-1746. 10.1101/gad.1556607, 1920168, 17626791.
7. Vervoorts J, Lüscher B. Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci 2008, 65:3255-3264. 10.1007/s00018-008-8296-7, 18636226.
8. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, Farace MG, Agami R. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007, 26:3699-3708. 10.1038/sj.emboj.7601790, 1949005, 17627278.
9. Sutterlüty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Müller U, Krek W. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999, 1:207-214. 10.1038/12027, 10559918.
10. Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S, Yoshida M, Nakayama K, Nakayama KI. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol 2004, 6:1229-1235. 10.1038/ncb1194, 15531880.
11. Ishida N, Kitagawa M, Hatakeyama S, Nakayama K. Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability. J Biol Chem 2000, 275:25146-25154. 10.1074/jbc.M001144200, 10831586.
12. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, Meloche S. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001, 20:6672-6682. 10.1093/emboj/20.23.6672, 125773, 11726503.
13. Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev 2006, 20:47-64. 10.1101/gad.1384406, 1356100, 16391232.
14. Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 2002, 277:14355-14358. 10.1074/jbc.C100762200, 11889117.
15. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999, 13:1181-1189. 10.1101/gad.13.9.1181, 316946, 10323868.
16. Kossatz U, Vervoorts J, Nickeleit I, Sundberg HA, Arthur JS, Manns MP, Malek NP. C-terminal phosphorylation controls the stability and function of p27kip1. EMBO J 2006, 25:5159-5170. 10.1038/sj.emboj.7601388, 1630410, 17053782.
17. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J, Atkinson MJ. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006, 103:15558-15563. 10.1073/pnas.0603877103, 1622862, 17030811.
18. Georgitsi M, Raitila A, Karhu A, Luijt RB, Aalfs CM, Sane T, Vierimaa O, Mäkinen MJ, Tuppurainen K, Paschke R, Gimm O, Koch CA, Gündogdu S, Lucassen A, Tischkowitz M, Izatt L, Aylwin S, Bano G, Hodgson S, De Menis E, Launonen V, Vahteristo P, Aaltonen LA. CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. Clin Endocrinol Metab 2007, 92:3321-3325.
19. Agarwal SK, Mateo CM, Marx SJ. Rare Germline Mutations in Cyclin-Dependent Kinase Inhibitor Genes in MEN1 and Related States. J Clin Endocrinol Metab 2009, 94:1826-1834. 10.1210/jc.2008-2083, 2684477, 19141585.
20. Igreja S, Chahal HS, Akker SA, Gueorguiev M, Popovic V, Damjanovic S, Burman P, Wass JA, Quinton R, Grossman AB, Korbonits M. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clin Endocrinol 2009, 70:259-264.
21. Owens M, Stals K, Ellard S, Vaidya B. Germline mutations in the CDKN1B gene encoding p27 Kip1 are a rare cause of multiple endocrine neoplasia type 1. Clin Endocrinol 2009, 70:499-500.
22. Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM, Clurman BE. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell 2000, 5:403-410. 10.1016/S1097-2765(00)80435-9, 10882081.
23. Sprague BL, McNally JG. FRAP analysis of binding: proper and fitting. Trends Cell Biol 2005, 15:84-91. 10.1016/j.tcb.2004.12.001, 15695095.
24. Yang H, Zonder JA, Dou QP. Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs 2009, 18:957-971. 10.1517/13543780903002074, 19505187.
25. Gillies JK, Lorimer IA. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 2007, 6:2005-2009.
26. Malek NP, Sundberg H, McGrew S, Nakayama K, Kyriakides TR, Roberts JM. A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase. Nature 2001, 413:323-327. 10.1038/35095083, 11565035.
27. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997, 3:231-234. 10.1038/nm0297-231, 9018245.
28. Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 2001, 98:5043-5048. 10.1073/pnas.081474898, 33160, 11309491.
29. Nickeleit I, Zender S, Sasse F, Geffers R, Brandes G, Sörensen I, Steinmetz H, Kubicka S, Carlomagno T, Menche D, Gütgemann I, Buer J, Gossler A, Manns MP, Kalesse M, Frank R, Malek NP. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008, 14:23-35. 10.1016/j.ccr.2008.05.016, 18598941.
30. Sha MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, Grever M. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004, 10:6111-6118. 10.1158/1078-0432.CCR-04-0422, 15447997.
31. Fero ML, Rivkin M, Tasch M, Porter P, Carow CW, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996, 85:733-744. 10.1016/S0092-8674(00)81239-8, 8646781.
32. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85:707-720. 10.1016/S0092-8674(00)81237-4, 8646779.
33. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996, 85:721-732. 10.1016/S0092-8674(00)81238-6, 8646780.